Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic Prices Offering of Stock and Warrants, Anticipates $6.2M in Proceeds

NEW YORK (GenomeWeb) – Transgenomic today priced its public offering of stock and warrants, expecting to raise $6.2 million in net proceeds. 

The firm is offering 3,573,899 shares of its common stock, as well as corresponding warrants to purchase 714,780 shares of its stock. The stocks and warrants will be sold in combination with one warrant to purchase .20 of a share of stock for each share of stock sold. The combined price for each share and corresponding warrant is $1.95, Transgenomic said. 

The warrants are exercisable immediately on the date of issuance at an exercise price of $2.24 per share. They will expire five years from the date of issuance. 

Transgenomic said that it plans to use net proceeds from the offering for working capital and general corporate purposes. Craig-Hallum Capital Group is the sole managing underwriter of the offering. 

In October the Omaha-based company said that it raised $2.4 million in gross proceeds from a private placement.